Embla Medical – Presentation of Interim report Q2 2024

You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.

Embla Medical will release its Q2 2024 report on 23 July 2024. The company’s management will present the results in a virtual live event with a Q&A session the same day at 13:00. Besides the financial results, you can get an update on recent business- and regulatory developments.

In Q1 2024, Embla Medical delivered an organic growth of 7% and reiterated its 2024 guidance for an organic sales growth of 5-8%. The growth is expected to be driven by continued volume growth and moderate price increases. The company also reiterated guidance on earnings, where the EBITDA margin before special items is expected to land at 19-20% (18% in 2023). The 2024 margin improvement is driven by expectations of a favorable product mix, increased efficiency in manufacturing, and scalability.

Embla Medical is a leading global provider of innovative mobility solutions in the medical technology space. Embla Medical improves people’s mobility through the delivery of Prosthetics, Bracing & Supports, and Patient Care. Headquartered in Iceland, the company employs over 4,000 people located across 36 countries worldwide. Embla Medical has extensive operations in the Americas, Europe, and Asia, as well as distributors in other markets.

Dislcaimer: HC Andersen Capital receives payment from Embla Medical for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis, 16.11, 17 June 2024.